Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Invested Capital (2019 - 2025)

Historic Invested Capital for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $25.9 million.

  • Eton Pharmaceuticals' Invested Capital rose 2882.72% to $25.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.9 million, marking a year-over-year increase of 2882.72%. This contributed to the annual value of $54.2 million for FY2024, which is 25044.91% up from last year.
  • Eton Pharmaceuticals' Invested Capital amounted to $25.9 million in Q3 2025, which was up 2882.72% from $26.7 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Invested Capital high stood at $54.4 million for Q1 2025, and its period low was $15.5 million during Q4 2023.
  • Moreover, its 5-year median value for Invested Capital was $21.1 million (2023), whereas its average is $24.7 million.
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 2996.67% in 2022, then surged by 25044.91% in 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Invested Capital (Quarter) stood at $22.9 million in 2021, then decreased by 19.35% to $18.5 million in 2022, then decreased by 16.17% to $15.5 million in 2023, then surged by 250.45% to $54.2 million in 2024, then crashed by 52.24% to $25.9 million in 2025.
  • Its last three reported values are $25.9 million in Q3 2025, $26.7 million for Q2 2025, and $54.4 million during Q1 2025.